"
Jacobs brings a strong scientific and medical background in
neuroscience. He has co-authored peer-reviewed research and review
articles in prestigious journals such as Journal of Neuroscience,
Neurosurgery, Experimental Neurology and Brain Research.S.

strokes fishguard

"I am excited to put my experience in neurological research to
work for StemCells, Inc.com

Apart from statements of historical facts, the text of this press
release constitutes forward-looking statements regarding , among other
things, the future business operations of StemCells, Inc. The forward-looking statements speak only as of the date of
this news release. Clinical trials of various neuroprotective agents are described
and failures of trials in stroke and head injury are analyzed with
suggestions for improving the selection of drugs and design of trials.

outings traumatic

Following completion of
these programs, Jacobs served as a resident neurosurgeon at the
University of California, San Francisco Medical Center.

is a development stage biotechnology company
focused on the discovery, development and commercialization of stem
cell-based therapies to treat diseases of the nervous system, liver
and pancreas.

fishguard traumatic

Over 300 products have been investigated for neuroprotective
effects including those from the categories of free radical
scavengers, anti-excitotoxic agents, apoptosis (programmed cell death)
inhibitors , anti-inflammatory agents, neurotrophic factors, metal ion
chelators, ion channel modulators and gene therapy.
The report contains a profile of 109 companies that have a
neuroprotective product or products.

strokes dimes

In his current capacity, Jacobs will lead the company's adult
human neural (brain) stem cell (HuCNS-SC) program through the clinical
development process. Jacobs has also worked with
neuroscience company Elan Pharmaceuticals as assistant director of
clinical affairs. ("the
Company"). StemCells does not undertake to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof. Diseases covered include
cerebrovascular disorders, traumatic brain injury, spinal cord injury,
Alzheimer's disease, Parkinson's disease, Huntington's disease ,
amyotrophic lateral sclerosis, multiple sclerosis, epilepsy and
ischemic optic neuropathy as well as retinal degeneration.

strokes templeton

----

Jacobs Brings Expertise in Managing and Implementing Clinical
Trials Involving Cell-Based Therapies for Neurological Disorders

StemCells, Inc.

carmarthenshire traumatic

He designed and
implemented phase II and III clinical studies, managed an ongoing
multi-center trial and closely interacted with the Food and Drug
Administration (FDA). These stem cells are expandable into cell banks for
therapeutic use, which demonstrates the feasibility of using normal,
non-genetically modified cells as cell-based therapies. Such statements reflect management's
current views and are based on certain assumptions that may or may not
ultimately prove valid.

staffed carmarthenshire

"
At Titan Pharmaceuticals , Jacobs led Titan's Central Nervous
System (CNS) clinical development efforts which included
Spheramine (R), a cell-based therapeutic for Parkinson's disease
developed in collaboration with Schering AG .
Market analysis shows that products currently used that have a
neuroprotective effect have a market value of 5.
For more information visit
http://www.

confidence southend

D. patents, as
well as 100 patent applications pending worldwide.

southend neurological

Alan
Jacobs will join the company as chief medical officer and vice
president of clinical research, neural program.S.researchandmarkets.com/reports/c1364) has
announced the addition of Neuroprotection - Drugs, Markets and
Companies to their offering
This report describes the role of neuroprotection in acute
disorders such as stroke and injuries of the nervous system as well as
in chronic diseases such as neurodegenerative disorders because many
of the underlying mechanisms of damage to neural tissues are similar
in all these conditions and several products are used in more than one
disorder. Some of the agents
are old established pharmaceuticals whereas others are new
biotechnology products.

caregivers emsworth

StemCells is
the only publicly traded company solely focused on stem cell research
and development and has more than 40 U.

Research and Markets: With Approval Of New Products And Takeover Of Markets For Obsolete Symptomatic Therapies Neuroprotection Market Value Will Rise $11.5 Bi

The report is supplemented with 59 tables and 8 figures.

Groups in this category serve the support needs of survivors, caregivers, and others who have been affected by stroke.

survivors encouraged

"I am committed to collaborating with the
full scientific team to reach StemCells' ultimate objective- -bringing
neural stem cell therapies to the clinic and providing treatments for
patients who currently have few viable medical options.stemcellsinc.

southend clinicians

"For these
reasons in particular, Alan will be an invaluable addition to
StemCells, Inc.

Pharmaceutical Writers/Business Editors/Health/Medical
Writers /Biotech Writers/Health Editors/Medical Editors

DUBLIN, Ireland----Research and
Markets (http: //www. Some of these
products are approved for other indications but are known to have a
neuroprotective effect.

carmarthenshire neurological

6 billion in all these areas. With the approval of new products and takeover
of markets for obsolete symptomatic therapies, the neuroprotection
market value will rise $11.

affected dimes

StemCells Inc. Names Alan Jacobs Chief Medical Officer and Vice President of Clinical Research Neural Program

He has also
served as an expert resource for the National Institutes of Health
NINDS Stroke Progress Review Group and Health Technology Center's
Expert Panel on Stem Cell Technology, both in 2001.
Jacobs received a Ph.

StemCells, Inc.1 billion out of a CNS
market value of $34.researchandmarkets .

stroke tbi

from the University of
Pennsylvania, School of Medicine, in 1995.
Pathomechanisms of diseases are described with steps at which
neuroprotective therapies are directed.com/reports/c1364

survivors ouse

"Alan has expertly directed two separate cell-based therapies
through late-stage clinical trials, and has worked with the leading
neuroscience companies in the world including Titan and Elan ," said
Martin McGlynn, chief executive officer of StemCells, Inc.

About StemCells, Inc.

tbi confidence

and will no doubt strengthen our scientific management
team.D from the University of Pennsylvania, David
Mahoney Institute of Neuroscience, and an M. StemCells is the first company to
directly identify and isolate human neural stem cells from normal
brain tissue. Although
anesthetics such as propofol are neuroprotective as well,
neuroprotection during surgery and anesthesia is discussed with the
aim of preventing and treating complications that result in CNS
damage. Although an up-to-date search of the
literature was performed and selected 500 references are included, a
considerable amount of information has not been published anywhere
else.

They offer opportunities for individuals to meet and share experiences in person or via the Internet.

rebuild survivors

Business Editors/Health Editors

PALO ALTO, Calif. Some of the products in
development at academic institutions that do not have a commercial
sponsor are also included.5 billion by the year 2010 when it will
constitute a major and important component of the CNS market.

caithness emsworth

in Electrical Engineering from Stanford University in
1988. and 100 non-U.

encouraged fishguard

The Company's stem cell programs seek to repair or
repopulate neural or other tissue that has been damaged or lost as a
result of disease or injury. The Company's actual results may vary
materially from those contemplated in the forward-looking statements
due to risks and uncertainties to which the Company is subject,
including uncertainties regarding the Company 's ability to obtain the
capital resources needed to continue its current research and
development operations and to conduct the research, preclinical
development and clinical trials necessary for regulatory approvals;
the uncertainty whether the FDA will approve the IND and permit the
Company to proceed to clinical testing; the uncertainty regarding the
outcome of the Phase I clinical trial and any other trials the Company
may conduct in the future; the uncertainty regarding the validity and
enforceability of issued patents; the uncertainty whether any products
that may be generated in the Company's stem cell programs will prove
clinically effective and not cause tumors or other side effects; the
uncertainty whether the Company will achieve revenues from product
sales or become profitable; uncertainties regarding the Company's
obligations in regard to its former encapsulated cell therapy
facilities in Rhode Island; and other factors that are described in
Exhibit 99 to the Company's Annual Report on Form 10-K titled
"Cautionary Factors Relevant to Forward-Looking Statements .

confidence stroke

(NASDAQ: STEM) today announced that Dr. He currently is a
member of the American Society of Experimental Neurotherapeutics and
the American Society of Neurotransplantation and Repair.S.

stroke disclaimers

, and to leverage its impressive preclinical
research supporting the safety and efficacy of neural stem cell
treatments ," said Jacobs. He also
received an M.

You are encouraged to read available disclaimers and privacy policies before participating in a group.

encouraged affected

Jacobs previously served as medical director of
Layton Biosciences, where he was responsible for clinical and
regulatory development of a neural cell line for the indications of
stroke and Parkinson's disease.

affected carers

Formerly the senior
director of clinical development at Titan Pharmaceuticals, Jacobs
offers valuable experience in managing clinical trial development of
cell-based therapies for indications such as Parkinson's disease and
stroke. Further information
about the Company is available on its web site at:
www."

By that
time neuroprotection will be an established part of the neurological
practice and measures will be available to achieve this effectively.